Reason: CGMP Deviations: Potential for cross-contamination due to product carryover during manufacturing.
Distributed: Nationwide in the USAReason: CGMP Deviations: Potential for cross-contamination due to product carryover during manufacturing.
Distributed: Nationwide in the USAReason: CGMP Deviations: Potential for cross-contamination due to product carryover during manufacturing.
Distributed: Nationwide in the USAReason: CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.
Distributed: Product was distributed nationwide.Reason: Chemical Contamination and Subpotent Drug: FDA analysis found product to contain methanol and below label claim for ethanol.
Distributed: TexasReason: Defective Delivery System: An incorrect 10 mL (12 mL) Luer (slip) syringe packaged in one lot of Zynrelef 400 mg/12 mg kit
Distributed: U.S.A. NationwideReason: Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below specification.
Distributed: Distributed in OhioReason: Lack of Assurance of Sterility
Distributed: Nationwide within the United StatesReason: Lack of Assurance of Sterility
Distributed: Nationwide within the United StatesReason: Presence of foreign tablet: 2.5 mg tablet in a 20 mg bottle of Prednisone Tablets
Distributed: US Nationwide